Compugen to Present at Upcoming Investor Conferences
Compugen Ltd. (Nasdaq: CGEN) announces participation in several virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) announces participation in several virtual investor conferences. Key events include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 AM ET, the Jefferies Virtual Healthcare Conference on November 18, 2020, at 5:35 AM ET, and the Evercore ISI HealthCONx Conference on December 1, 2020, at 9:40 AM ET. Live webcasts will be available on the Compugen website, with replays accessible post-event. The company is focused on cancer immunotherapy, with its lead product COM701 in Phase 1 clinical studies.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was +0.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON, Israel, Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that management will present at the following upcoming virtual investor conferences:
Event: Stifel 2020 Virtual Healthcare Conference
Date: Tuesday, November 17, 2020
Presentation Time: 8:40 AM ET
Event: Jefferies Virtual Healthcare Conference
Date: Wednesday, November 18, 2020
Presentation Time: 5:35 AM ET (10:35 AM GMT)
Event: Evercore ISI 3rd Annual HealthCONx Conference
Date: Tuesday, December 1, 2020
Presentation Time: 9:40 AM ET
A live webcast of each presentation will be accessible in the Investor Relations section of the Compugen website at www.cgen.com. Replays will also be available following each live event.
In addition, the Company will also be participating in the SVB Leerink Oncology 1x1 Day on Thursday, November 19, 2020.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. The Company's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com
Tel: +1 (646) 597-6989
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1 (646) 751-4361
View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-investor-conferences-301169600.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.